Schedule One Update - Abingdon Health Plc | RNS | Ticker

Schedule One Update - Abingdon Health Plc

RNS Announcement

RNS Number : 1360I

AIM

10 December 2020

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Abingdon Health plc ("Abingdon Health" or the "Company")

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

York Biotech Campus,

Sand Hutton,

York, England,

YO41 1LZ

The Company's registered office is the same address as which it trades.

COUNTRY OF INCORPORATION:

England and Wales

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.abingdonhealth.com (from Admission)

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Established in 2008, Abingdon Health is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries. Services offered by the Company to its clients including product development, regulatory support, technology transfer and commercial manufacturing.

The Company has developed and is manufacturing the AbC-19^TM Rapid Test, an antibody test for Covid-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The Company is also working with three customers to transfer their Covid-19 antigen tests to manufacture, and is manufacturing a component of a rapid PCR (polymerase chain reaction) test. The Company also produces lateral flow tests covering non-Covid-19 applications in areas such as self-test HIV, equine infection, human fertility, blood cancer and other infectious diseases across the healthcare sector as well as other areas such as fuel contamination in the aviation sector and testing for water contaminants.

The Company's main country of operation is the United Kingdom.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

Number of ordinary shares: 95,699,114

Nominal value of ordinary shares on Admission: £0.00025

Issue price per ordinary share: 96.0 pence

There are no shares to be held in treasury.

There are no restrictions on the transfer of securities to be admitted to trading.

CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Capital to be raised on Admission: £22.0 million

Anticipated market capitalisation on Admission: £91.9 million

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

67.9%

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

Not applicable

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Dr Christopher (Chris) William Hand, Non-Executive Chairman

Chris Henry Francis Yates, Chief Executive Officer

Scott Andrew Page, Finance Director

Lyn Dafydd Rees, Independent Non-Executive Director

Mary Geraldine Tavener, Independent Non-Executive Director

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Significant Shareholder	Before Admission*	After Admission
NPIF YHTV Equity LP (acting by its general partner Enterprise Ventures (General Partner NPIF YHTV Equity) Limited, a wholly owned subsidiary of Mercia Asset Management PLC)	24.8%	18.9%
Dr Christopher (Chris) William Hand	15.4%	11.7%
CatenaLucis LLC**	10.0%	7.6%
Chris Henry Francis Yates	8.9%	6.8%
Thornapple LLP**	8.4%	6.4%
Touchstone Innovations Businesses LLP	5.7%	4.4%
University of Birmingham	4.7%	3.6%

* Assumes all outstanding loan notes are converted into equity and employee EMI share options are exercised prior to IPO.

** Max Duckworth, a former Non-Executive Director of the Company, has equity interests in 43.78% of CatenaLucis LLC and 100% of Thornapple LLP.

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

Not applicable

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

i.) 30 June

ii.) 30 June 2020

iii.) Unaudited results for the six months to 31 December 2020 - by 31 March 2021

Audited results for the year to 30 June 2021 - by 31 December 2021

Unaudited results for the six months to 31 December 2021 - by 31 March 2022

EXPECTED ADMISSION DATE:

15 December 2020

NAME AND ADDRESS OF NOMINATED ADVISER:

N+1 Singer

1 Bartholomew Lane

London

EC2N 2AX

NAME AND ADDRESS OF BROKER:

N+1 Singer

1 Bartholomew Lane

London

EC2N 2AX

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

www.abingdonhealth.com (from the date of Admission)

THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

The Quoted Companies Alliance (QCA) Corporate Governance Code.

DATE OF NOTIFICATION:

10 December 2020

NEW/ UPDATE:

UPDATE

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AIMFLFVDFRLAIII

RNS metadata

Title: Schedule One Update - Abingdon Health Plc
Time: 08:00:02
Date: 10 Dec 2020
Category: Capital structure
ID: 1360I